[Featured Stock] IntronBio Surges on US Patent Application for Technology Maximizing mRNA Vaccine Efficiency

[Asia Economy Reporter Minwoo Lee] IntronBio's stock price is on the rise. The news of filing a U.S. patent related to platform technology that enhances the efficiency of mRNA (messenger ribonucleic acid)-based vaccines appears to have acted as a positive factor.

As of 10:18 AM on the 15th, IntronBio's stock price recorded 21,850 KRW, up 4.55% compared to the previous day. At one point in the morning, it rose to 22,350 KRW, up 6.94% from the previous day. The patent filing announcement made on this day seems to have had a positive impact.

IntronBio announced on the same day that it has filed a U.S. patent related to the mRNA vaccine platform technology called 'mRNA mucosal vaccine technology.' The patent pertains to technology that enhances the effect of mucosal vaccines, and it is explained as a platform technology that can maximize the efficiency of mucosal vaccines developed using the bacteriophage display technique.

Kang Sanghyun, head of research at IntronBio, stated, "The newly developed mRNA mucosal vaccine patent technology can be utilized not only for mRNA vaccines aimed at preventing viral diseases but also for various mRNA-based pharmaceutical technologies. It is a technology with very high technical value that can be widely expanded and applied in the development of various follow-up pipelines such as anticancer drugs, allergy treatments, and anti-aging drugs."

This content was produced with the assistance of AI translation services.